Clinical trial NCT03401229: Efficacy and Safety Study of Benralizumab for Patients With Severe Nasal Polyposis
Official title: A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Phase 3 Efficacy and Safety Study Of Benralizumab in Patients With Severe Nasal Polyposis
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Nasal Polyposis
Keywords: Polyps
Nasal polyps
Nasal polyposis
Nose diseases
Respiratory tract diseases
Otorhinolaryngologic diseases
Benralizumab
Mometasone furoate
Lead sponsor: AstraZeneca
Sponsor class: INDUSTRY
First posted: 2018-01-17
Enrollment: 413
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The aim of this present study is to investigate the use of benralizumab as treatment for severe nasal polyposis. The effect of benralizumab on nasal polyps will be assessed over a 56 weeks of treatment period in patients with severe bilateral nasal polyposis who are still symptomatic despite standard of care therapy, i.e current use of intranasal corticosteroids (INCS) and prior surgery and/or use of systemic corticosteroids. The first 200 patients that complete the 56-week treatment will have a 6 month follow-up (FU) period without dosing.


Eligibility criteria: Inclusion Criteria:

1. Capable of giving signed informed consent, which includes compliance with the requirements and restrictions, listed in the informed consent form (ICF) and in protocol.
2. Provision of signed and dated, written informed consent form (ICF) prior to any mandatory study specific procedures, sampling, and analyses and according to international guidelines and/or applicable European Union (EU) guidelines.
3. Provision of signed and dated written genetic informed consent in patients that agree to participate in the genetic sampling, prior to collection of sample for genetic analysis.
4. Female or male patients aged 18 to 75 years inclusive, at the time of signing the ICF.
5. Patients with bilateral sinonasal polyposis that, despite treatment with a stable dose of intranasal corticosteroids (INCS) for at least 4 weeks prior to V1, in addition to history of treatment with systemic (SCS -oral, parenteral) or prior surgery for nasal polyposis (NP), have severity consistent with a need for surgery as described by:

   * A minimum total Nasal Polyp Score (NPS) of 5 out of a maximum score of 8 (with a unilateral score of at least 2 for each nostril) at V1, and continuously maintained at V2 to meet the randomization criterion, as determined by the study Imaging Core Lab;
   * Ongoing symptoms for at least 12 weeks prior to V1;
   * Patient-reported moderate to severe nasal blockage score (NBS) 2 or 3 over the 2-weeks prior to V1 (2-week recall assessment of symptoms, scores 0-none to 3-severe).
6. SNOT-22 total score ≥ 30 at enrolment.

   Patient must meet the following criteria (points 7-10) at the randomization visit:
7. At least 8 days of evaluable daily diary data in the 14-day period prior to randomization (baseline bi-weekly mean score collected from study Day -13 to study Day 0).
8. At randomization, a bi-weekly mean NBS ≥ 1.5.
9. SNOT-22 total score ≥ 30 at randomization.
10. At least 70% compliance with INCS during the run-in period based on daily diary.
11. Patients with a minimum weight of 40kg.
12. Negative serum pregnancy test result and a negative urine pregnancy test at randomization for female patients of childbearing potential.
13. Women of childbearing potential (WOCBP) must use an effective form of birth control as defined in the Clinical Study Protocol (CSP).

15. Male subjects who are sexually active must be surgically sterile at least one year prior to Visit 1 or must use an adequate method of contraception (condom or condom with spermicide depending on local regulations) from the first dose of IP until 16 weeks after their last dose. Men with a partner or partners who is (are) not of childbearing potential are exempt of these requirements

Exclusion Criteria:

1. Patients who have undergone any nasal and/or sinus surgery within 3 months prior to V1.
2. Patients with conditions or concomitant disease that makes them non evaluable for the co-primary efficacy endpoint such as:

   * Unilateral antrochoanal polyps;
   * Nasal septal deviation that occludes at least one nostril;
   * Acute sinusitis, nasal infection, or upper respiratory infection at screening or in the 2 weeks before screening;
   * Current rhinitis medicamentosa;
   * Allergic fungal rhinosinusitis (AFRS) or Allergic fungal sinusitis (AFS);
   * Nasal cavity tumors.
3. Clinically important comorbidities that could confound interpretation of clinical efficacy results including, but not limited to: active upper or lower respiratory tract infection, cystic fibrosis, primary ciliary dyskinesia, eosinophilic diseases other than asthma (e.g. allergic bronchopulmonary aspergillosis/mycosis, eosinophilic granulomatosis with polyangitis \[Churg-Strauss syndrome\], hypereosinophilic syndromes), granulomatosis with polyangitis (Wegener's granulomatosis), Young's syndrome, etc.
4. Any disorder, including but not limited to: cardiovascular, gastrointestinal, hepatic, renal, neurological, musculoskeletal, infectious, endocrine, metabolic, haematological, psychiatric, or major physical impairment that is not stable in the opinion of the Investigator or AstraZeneca and could:

   * Affect the safety of the patient throughout the study;
   * Influence the findings of the studies or their interpretations;
   * Impede the patient's ability to complete the entire duration of study.
5. Patients experiencing an asthma exacerbation requiring systemic (oral and/or parenteral) corticosteroids treatment or hospitalization (\>24hrs) for treatment of asthma within 4 weeks prior to V1.
6. History of anaphylaxis to any biologic therapy or vaccine.
7. Known history of allergy or reaction to any component of the Investigational Product (IP) formulation.
8. History of Guillain-Barré syndrome.
9. A helminth parasitic infection diagnosed within 24 weeks prior to V1 and has not been treated with, or has failed to respond to standard of care therapy.
10. Current malignancy, or history of malignancy, except for: - Patients who have had basal cell carcinoma, localized squamous cell carcinoma of the skin, or in situ carcinoma of the cervix are eligible provided that patient is in remission and curative therapy was completed at least 12 months prior to V1; - Patients who have had other malignancies are eligible provided that the patient is in remission and curative therapy was completed at least 5 years prior to V1.

    NOTE: Hormonal therapy is allowed. As long as the cancer is in remission for 5 years, the patient is eligible.
11. Any clinically significant cardiac disease or any electrocardiogram (ECG) abnormality obtained during the screening/run-in period, which may put the patient at risk or interfere with study assessments.
12. Positive hepatitis B surface antigen, or hepatitis C virus antibody serology (confirmed by additional testing, e.g. hepatitis C RNA test, if indicated), or a positive medical history for hepatitis B or C (Note: Patients with history of hepatitis B vaccination without history of hepatitis B are allowed to enroll).
13. History of known immunodeficiency disorder, including a positive human immunodeficiency virus (HIV) test.
14. Infection requiring systemic antibiotics (Ab) within 14 days prior to V1
15. Use of immunosuppressive medication (including but not limited to: methotrexate, troleandomycin, cyclosporine, azathioprine, or any experimental anti-inflammatory therapy) within 3 months prior to V1.
16. Receipt of any marketed or investigational biologic products (monoclonal or polyclonal antibody) within 6 months or 5 half-lives prior to the date informed consent, is obtained, whichever is longer, prior to V1 and during the study period. This also applies to patients who previously participated in clinical studies and were treated with monoclonal antibodies (e.g. mepolizumab, reslizumab, dupilumab, omalizumab). Note that this restriction do not apply to patients, who are confirmed to have only received treatment with placebo.
17. Previous receipt of benralizumab.
18. Receipt of immunoglobulin or blood products within 30 days prior to V1.
19. Receipt of live attenuated vaccines 30 days prior to the date of randomization.
20. Receipt of any investigational drug within 30 days or 5 half-lives whichever is longer prior to randomization.
21. Receipt of systemic corticosteroid 4 weeks prior to V1, or a scheduled systemic corticosteroid treatment during the study period.

    NOTE: Sustained release steroids (e.g. Kenalog \[Triamcinolone acetonide\]) or depot injections require minimum 6 weeks washout prior to V1.
22. Receipt of leukotriene antagonist/modifiers for patients who were not on a continuous stable dose for ≥30 days prior to V1.
23. Concurrent enrolment in another clinical drug interventional trial.
24. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) level ≥ 3 times the upper limit of normal (ULN) confirmed during screening period.
25. Previous randomization in the present study.
26. Planned major surgical procedures or scheduled NP surgery at the time of the study enrolment and randomization.
27. Initiated or is being maintained on an aspirin desensitization regimen for the management of aspirin exacerbated respiratory disease (AERD) at the time of study enrolment or during the run-in period.
28. For women only - currently pregnant (or intend to become pregnant), breastfeeding or lactating.

Primary outcomes:
measure: Change From Baseline in Total NPS at Week 40
timeFrame: Baseline to week 40
measure: Change From Baseline in NBS at Week 40
timeFrame: Baseline to week 40
Secondary outcomes:
measure: Change From Baseline in SNOT-22 at Week 40
timeFrame: Baseline to week 40
measure: Time to First NP Surgery and/or SCS Use for NP to Week 56
timeFrame: Baseline to week 56
measure: Time to the First NP Surgery up to Week 56
timeFrame: Baseline to week 56
measure: Change From Baseline in DSS at Week 40
timeFrame: Baseline to week 40
measure: Change From Baseline in NPS at Week 56
timeFrame: Baseline to week 56
measure: Change From Baseline in NBS at Week 56
timeFrame: Baseline to week 56
measure: Change From Baseline in SNOT-22 at Week 56
timeFrame: Baseline to week 56
measure: Change From Baseline in DSS at Week 56
timeFrame: Baseline to week 56
measure: Change From Baseline in LMS at EOT/IPD
timeFrame: Baseline to EOT/IPD, up to 56 weeks
measure: Percentage of Subjects With NP Surgery
timeFrame: Baseline to week 56
measure: Percentage of Subjects With SCS_NP
timeFrame: Baseline to week 56
measure: Percentage of Subjects With NP Surgery or SCS_NP
timeFrame: Baseline to week 56
measure: Time to First SCS_NP up to Week 56
timeFrame: Baseline to week 56
measure: Total Number of Courses of SCS for NP
timeFrame: Baseline to week 56
measure: Total SCS_NP Dose (a) Used (mg)
timeFrame: Baseline to week 56
measure: Total Duration of SCS_NP (Days)
timeFrame: Baseline to week 56
measure: Annual SCS_NP Use Rate Comparison by Period, Negative Binomial Model
timeFrame: Baseline to week 56
measure: Change From Baseline in TSS at Week 40
timeFrame: Baseline to week 40
measure: Change From Baseline in Difficulty With Sleeping Due to Nasal Symptoms at Week 40
timeFrame: Baseline to week 40
measure: Change From Baseline in Difficulty With Daily Activities Due to Nasal Symptoms at Week 40
timeFrame: Baseline to week 40
measure: Change From Baseline in UPSIT Score in Males at Week 40
timeFrame: Baseline to week 40
measure: Change From Baseline in UPSIT Score in Females at Week 40
timeFrame: Baseline to week 40
measure: Change From Baseline in Sinus Severity Score at EOT/IPD
timeFrame: Baseline to EOT/IPD, up to 56 weeks
measure: Change From Baseline in SF-36v2 Physical Component Summary at Week 56
timeFrame: Baseline to week 56
measure: Change From Baseline in SF-36v2 Mental Component Summary at Week 56
timeFrame: Baseline to week 56
measure: Change From Baseline in SF-36v2 Physical Functioning at Week 56
timeFrame: Baseline to week 56
measure: Change From Baseline in SF-36v2 Role Limitations Due to Physical Health at Week 56
timeFrame: Baseline to week 56
measure: Change From Baseline in SF-36v2 Bodily Pain at Week 56
timeFrame: Baseline to week 56
measure: Change From Baseline in SF-36v2 General Health Perceptions at Week 56
timeFrame: Baseline to week 56
measure: Change From Baseline in SF-36v2 Vitality at Week 56
timeFrame: Baseline to week 56
measure: Change From Baseline in SF-36v2 Social Functioning at Week 56
timeFrame: Baseline to week 56
measure: Change From Baseline in SF-36v2 Role Limitations Due to Emotional Problems at Week 56
timeFrame: Baseline to week 56
measure: Change From Baseline in SF-36v2 Mental Health at Week 56
timeFrame: Baseline to week 56
Other outcomes:
Locations:
city: Birmingham
country: United States
facility: Research Site
state: Alabama
city: Fresno
country: United States
facility: Research Site
state: California
city: Huntington Beach
country: United States
facility: Research Site
state: California
city: La Mesa
country: United States
facility: Research Site
state: California
city: Los Angeles
country: United States
facility: Research Site
state: California
city: Los Angeles
country: United States
facility: Research Site
state: California
city: Orange
country: United States
facility: Research Site
state: California
city: Roseville
country: United States
facility: Research Site
state: California
city: Walnut Creek
country: United States
facility: Research Site
state: California
city: Centennial
country: United States
facility: Research Site
state: Colorado
city: Glenwood Springs
country: United States
facility: Research Site
state: Colorado
city: Washington
country: United States
facility: Research Site
state: District of Columbia
city: Lake Mary
country: United States
facility: Research Site
state: Florida
city: Atlanta
country: United States
facility: Research Site
state: Georgia
city: Decatur
country: United States
facility: Research Site
state: Georgia
city: Chicago
country: United States
facility: Research Site
state: Illinois
city: Chicago
country: United States
facility: Research Site
state: Illinois
city: Des Moines
country: United States
facility: Research Site
state: Iowa
city: Kansas City
country: United States
facility: Research Site
state: Kansas
city: Louisville
country: United States
facility: Research Site
state: Kentucky
city: Baltimore
country: United States
facility: Research Site
state: Maryland
city: Boston
country: United States
facility: Research Site
state: Massachusetts
city: Boston
country: United States
facility: Research Site
state: Massachusetts
city: Rochester
country: United States
facility: Research Site
state: Minnesota
city: Lincoln
country: United States
facility: Research Site
state: Nebraska
city: Bronx
country: United States
facility: Research Site
state: New York
city: Hewlett
country: United States
facility: Research Site
state: New York
city: New Windsor
country: United States
facility: Research Site
state: New York
city: New York
country: United States
facility: Research Site
state: New York
city: New York
country: United States
facility: Research Site
state: New York
city: New York
country: United States
facility: Research Site
state: New York
city: New York
country: United States
facility: Research Site
state: New York
city: New York
country: United States
facility: Research Site
state: New York
city: New York
country: United States
facility: Research Site
state: New York
city: Plainview
country: United States
facility: Research Site
state: New York
city: White Plains
country: United States
facility: Research Site
state: New York
city: Charlotte
country: United States
facility: Research Site
state: North Carolina
city: Winston-Salem
country: United States
facility: Research Site
state: North Carolina
city: Oklahoma City
country: United States
facility: Research Site
state: Oklahoma
city: Philadelphia
country: United States
facility: Research Site
state: Pennsylvania
city: Pittsburgh
country: United States
facility: Research Site
state: Pennsylvania
city: Charleston
country: United States
facility: Research Site
state: South Carolina
city: Conroe
country: United States
facility: Research Site
state: Texas
city: Houston
country: United States
facility: Research Site
state: Texas
city: North Logan
country: United States
facility: Research Site
state: Utah
city: Norfolk
country: United States
facility: Research Site
state: Virginia
city: Richmond
country: United States
facility: Research Site
state: Virginia
city: Spokane
country: United States
facility: Research Site
state: Washington
city: Graz
country: Austria
facility: Research Site
city: Linz
country: Austria
facility: Research Site
city: Salzburg
country: Austria
facility: Research Site
city: St. Pölten
country: Austria
facility: Research Site
city: Wien
country: Austria
facility: Research Site
city: Bruxelles
country: Belgium
facility: Research Site
city: Gent
country: Belgium
facility: Research Site
city: Leuven
country: Belgium
facility: Research Site
city: Vancouver
country: Canada
facility: Research Site
state: British Columbia
city: Hamilton
country: Canada
facility: Research Site
state: Ontario
city: London
country: Canada
facility: Research Site
state: Ontario
city: Mississauga
country: Canada
facility: Research Site
state: Ontario
city: Ottawa
country: Canada
facility: Research Site
state: Ontario
city: Montreal
country: Canada
facility: Research Site
state: Quebec
city: Montreal
country: Canada
facility: Research Site
state: Quebec
city: Montreal
country: Canada
facility: Research Site
state: Quebec
city: Trois-Rivières
country: Canada
facility: Research Site
state: Quebec
city: Quebec
country: Canada
facility: Research Site
city: Quebec
country: Canada
facility: Research Site
city: Aalborg
country: Denmark
facility: Research Site
city: Aarhus N
country: Denmark
facility: Research Site
city: Hillerød
country: Denmark
facility: Research Site
city: Hvidovre
country: Denmark
facility: Research Site
city: København NV
country: Denmark
facility: Research Site
city: Køge
country: Denmark
facility: Research Site
city: Næstved
country: Denmark
facility: Research Site
city: Odense C
country: Denmark
facility: Research Site
city: Vejle
country: Denmark
facility: Research Site
city: Aschaffenburg
country: Germany
facility: Research Site
city: Berlin
country: Germany
facility: Research Site
city: Dreieich
country: Germany
facility: Research Site
city: Dresden
country: Germany
facility: Research Site
city: Düsseldorf
country: Germany
facility: Research Site
city: Göttingen
country: Germany
facility: Research Site
city: Heidelberg
country: Germany
facility: Research Site
city: Lübeck
country: Germany
facility: Research Site
city: Münster
country: Germany
facility: Research Site
city: Wiesbaden
country: Germany
facility: Research Site
city: Budapest
country: Hungary
facility: Research Site
city: Budapest
country: Hungary
facility: Research Site
city: Debrecen
country: Hungary
facility: Research Site
city: Eger
country: Hungary
facility: Research Site
city: Nyíregyháza
country: Hungary
facility: Research Site
city: Pécs
country: Hungary
facility: Research Site
city: Veszprém
country: Hungary
facility: Research Site
city: Nadarzyn
country: Poland
facility: Research Site
city: Strzelce Opolskie
country: Poland
facility: Research Site
city: Warszawa
country: Poland
facility: Research Site
city: Wrocław
country: Poland
facility: Research Site
city: Wrocław
country: Poland
facility: Research Site
city: Łódź
country: Poland
facility: Research Site
Study officials:
affiliation: University Hospital Ghent, de Pintelaan 185, 9000 Ghent, Belgium
name: Claus Bachert, Prof. dr. h.c.
role: PRINCIPAL_INVESTIGATOR
References:
citation: Bachert C, Han JK, Desrosiers MY, Gevaert P, Heffler E, Hopkins C, Tversky JR, Barker P, Cohen D, Emson C, Martin UJ, Shih VH, Necander S, Kreindler JL, Jison M, Werkstrom V. Efficacy and safety of benralizumab in chronic rhinosinusitis with nasal polyps: A randomized, placebo-controlled trial. J Allergy Clin Immunol. 2022 Apr;149(4):1309-1317.e12. doi: 10.1016/j.jaci.2021.08.030. Epub 2021 Sep 29.
citation: Geng B, Dilley M, Anterasian C. Biologic Therapies for Allergic Rhinitis and Nasal Polyposis. Curr Allergy Asthma Rep. 2021 Jun 10;21(6):36. doi: 10.1007/s11882-021-01013-y.